741265-15-6

Upstream product

• 95-79-4 5-chloro-2-methyl-benzenamine 
• 386704-06-9 2-chloro-6-(trifluoromethyl)nicotinonitrile 
• 116548-04-0 2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carbonitrile 
• 59938-06-6 4-ethoxy-1,1,1-trifluoro-3-butene-2-one 

Downstream Products

• 1018788-40-3 C₂₀H₁₁Cl₄F₃N₂O₂ 
• 1018788-38-9 C₂₀H₁₂Cl₃F₃N₂O₂ 
• 1018788-32-3 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-34-5 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-36-7 C₂₀H₁₃Cl₂F₃N₂O₂ 
• 1018788-42-5 C₂₁H₁₆ClF₃N₂O₃ 
• 1018788-46-9 3,5-dimethoxyphenyl 2-(5-chloro-2-methylphenylamino)-6-(trifluoromethyl)nicotinate 
• 1018788-44-7 4-methoxyphenyl 2-(5-chloro-2-methylphenylamino)-6-(trifluoromethyl)nicotinate 

Relevant academic research and scientific papers

2-(Arylamino)-6-(trifluoromethyl)nicotinic acid derivatives: New HIV-1 RT dual inhibitors active on viral replication

The persistence of the AIDS epidemic, and the life-long treatment required, indicate the constant need of novel HIV-1 inhibitors. In this scenario the HIV-1 Reverse Transcriptase (RT)-associated ribonuclease H (RNase H) function is a promising drug target. Here we report a series of compounds, developed on the 2-amino-6-(trifluoromethyl)nicotinic acid scaffold, studied as promising RNase H dual inhibitors. Among the 44 tested compounds, 34 inhibited HIV-1 RT-associated RNase H function in the low micromolar range, and seven of them showed also to inhibit viral replication in cell-based assays with a selectivity index up to 10. The most promising compound, 21, inhibited RNase H function with an IC50 of 14 μM and HIV-1 replication in cell-based assays with a selectivity index greater than 10. Mode of action studies revealed that compound 21 is an allosteric dual-site compound inhibiting both HIV-1 RT functions, blocking the polymerase function also in presence of mutations carried by circulating variants resistant to non-nucleoside inhibitors, and the RNase H function interacting with conserved regions within the RNase H domain. Proving compound 21 as a promising lead for the design of new allosteric RNase H inhibitors active against viral replication with not significant cytotoxic effects.

2-(3-Fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: Structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3- ylmethyl) C-region

A series of N-(2-amino-6-trifluoromethylpyridin-3-ylmethyl)-2-(3-fluoro-4- methylsulfonylaminophenyl)propanamides were designed combining previously identified pharmacophoric elements and evaluated as hTRPV1 antagonists. The SAR analysis indicated that specific hydrophobic interactions of the 2-amino substituents in the C-region of the ligand were critical for high hTRPV1 binding potency. In particular, compound 49S was an excellent TRPV1 antagonist (K i(CAP) = 0.2 nM; IC50(pH) = 6.3 nM) and was thus approximately 100- and 20-fold more potent, respectively, than the parent compounds 2 and 3 for capsaicin antagonism. Furthermore, it demonstrated strong analgesic activity in the rat neuropathic model superior to 2 with almost no side effects. Compound 49S antagonized capsaicin induced hypothermia in mice but showed TRPV1-related hyperthermia. The basis for the high potency of 49S compared to 2 is suggested by docking analysis with our hTRPV1 homology model in which the 4-methylpiperidinyl group in the C-region of 49S made additional hydrophobic interactions with the hydrophobic region.

NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS

The present invention relates to novel vanilloid receptor ligands, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use of these compounds for the production of pharmaceutical preparations.

Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity

A new series of 2-arylamino-6-trifluoromethyl-3-carboxylic acid derivatives was synthesized and assayed in vivo for their analgesic properties by means of writhing test in rats. When compared to aspirin, ibuprofen and flufenamic acid some of the new compo